epas1-protein

📖 Wiki Page

protein2900 wordssynced 2026-04-02

epas1-protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">epas1-protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>EPAS1 / HIF-2α</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>EPAS1</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y5Q3</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~96-118 kDa (depending on post-translational modifications)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Nucleus and cytoplasm (-regulated by oxygen)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>bHLH-PAS transcription factor family</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Highest in endothelial cells, neurons, cardiomyocytes, type II pneumocytes</td>
</tr>
<tr>
<td class="label">Homologs</td>
<td>HIF-1α (EPAS1 shares 48% sequence identity with HIF-1α)</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Roxadustat</td>
<td>Approved (CKD)</td>
</tr>
<tr>
<td class="label">Vadadustat</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Daprodustat</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Molidustat</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="colo

...

epas1-protein

Introduction

EPAS1 (Endothelial PAS Domain Protein 1), also known as HIF-2α (Hypoxia-Inducible Factor-2 alpha), is a member of the HIF family of transcription factors that serve as the master regulators of cellular oxygen homeostasis. While [HIF-1α](/proteins/hif-1alpha-protein) is widely expressed, EPAS1 demonstrates more tissue-specific expression patterns with particularly high levels in endothelial cells, [neurons](/cell-types/neurons), and glial cells. This differential expression pattern, combined with distinct target gene profiles, positions EPAS1 as a critical player in neurobiology and neurodegenerative disease pathogenesis. [@semenza1999]

Overview

Protein Structure and Domains

N-Terminal bHLH Domain (Amino Acids 1-70)

The basic helix-loop-helix (bHLH) domain serves as the primary DNA-binding module. This domain recognizes and binds to the hypoxia response element (HRE) with the consensus sequence 5'-RCGTG-3' found in the promoters of target genes. The bHLH domain facilitates both DNA binding and protein dimerization, forming the foundation for transcriptional activation. [@semenza1999]

PAS Domains

EPAS1 contains two PAS domains that are critical for protein-protein interactions and dimer formation:

PAS-A Domain (Amino Acids 100-170): Mediates primary dimerization with HIF-1β (ARNT)
PAS-B Domain (Amino Acids 240-310): Provides additional dimerization interface and environmental sensing

These PAS domains function as molecular sensors that detect changes in cellular oxygen tension and enable conformational changes necessary for transcriptional regulation.

Oxygen-Dependent Degradation Domain (ODD)

The ODD domain (amino acids 400-600) serves as the primary regulatory region controlling EPAS1 protein stability under different oxygen conditions. Under normoxic conditions, specific prolyl hydroxylases (PHD1, PHD2, and PHD3) hydroxylate two conserved proline residues within this domain, allowing recognition by the Von Hippel-Lindau (VHL) tumor suppressor protein, leading to proteasomal degradation. This oxygen-dependent regulation represents the fundamental mechanism by which cells sense and respond to hypoxia. [@semenza1999]

Transactivation Domain (TAD)

The C-terminal transactivation domain (amino acids 700-870) facilitates interactions with transcriptional coactivators including CBP/p300. This domain contains the transcriptional activation function and determines the magnitude of gene expression activation.

Normal Physiological Functions

Cellular Oxygen Sensing

As the oxygen-sensitive subunit of HIF-2, EPAS1 heterodimerizes with HIF-1β (ARNT) to form the active HIF-2 transcription factor complex. This complex binds to hypoxia response elements (HREs) in target gene promoters and activates a coordinated transcriptional program that includes:

Vascular Endothelial Growth Factor ([VEGF](/proteins/vgf)): Primary angiogenic factor activating blood vessel formation
Erythropoietin ([EPO](/proteins/erythropoietin)): Hormone stimulating red blood cell production
GLUT1 (SLC2A1): Glucose transporter increasing cellular glucose uptake
LDHA: Lactate dehydrogenase supporting glycolytic metabolism
PDK1: Pyruvate dehydrogenase kinase inhibiting TCA cycle and reducing oxygen consumption

This transcriptional response enables cells to adapt to reduced oxygen availability, maintaining cellular homeostasis and survival under hypoxic conditions. [@semenza1999]

Neurovascular Regulation

Within the brain, EPAS1 plays essential roles in neurovascular coupling and blood flow regulation:

Regulates [VEGF](/proteins/vgf) expression controlling cerebral angiogenesis
Modulates endothelial cell function and blood-brain barrier integrity
Controls expression of glucose transporters at the blood-brain barrier
Coordinates metabolic coupling between neurons and blood vessels

The neurovascular functions of EPAS1 position it as a critical interface between neuronal activity and cerebral blood flow, with implications for understanding the vascular components of neurodegenerative diseases. [@cheng2017]

Neural Stem Cell Maintenance

EPAS1 participates in maintaining neural stem cell populations through regulation of:

Stem cell proliferation and self-renewal
Differentiation decisions during neurogenesis
Response to hypoxic niches in the subventricular zone
Expression of stemness factors including Oct4 and Sox2

This function connects EPAS1 to adult neurogenesis and potential regenerative therapies for neurodegenerative diseases. [@yang2018]

Role in Neurodegenerative Diseases

Alzheimer's Disease

EPAS1 dysfunction contributes to Alzheimer's disease pathogenesis through multiple mechanisms:

Amyloid-VEGF Interaction: [Amyloid-beta](/proteins/amyloid-beta) accumulation disrupts normal VEGF signaling, which is regulated by EPAS1. This disruption contributes to neurovascular dysfunction and impaired cerebral blood flow. [@ou2016]

Hypoxia Response Dysregulation: In AD brain, chronic microhypoxia around amyloid plaques leads to prolonged EPAS1 activation. While initially protective, sustained activation may contribute to inflammatory responses and disease progression. [@singh2012]

Mitochondrial Dysfunction: EPAS1 regulates genes controlling mitochondrial function and biogenesis. Dysregulation contributes to the mitochondrial dysfunction observed in AD neurons. [@gao2015]

Blood-Brain Barrier Breakdown: EPAS1 dysregulation affects tight junction proteins and endothelial function, contributing to BBB disruption in AD. [@zhang2019]

Inflammatory Responses: EPAS1 activation influences cytokine production and microglial activation, modulating neuroinflammation in AD brain. [@singh2012]

Parkinson's Disease

EPAS1 plays significant roles in dopaminergic neuron survival and PD pathogenesis:

Dopaminergic Neuron Vulnerability: EPAS1 is highly expressed in dopaminergic neurons of the substantia nigra, which are selectively vulnerable in PD. Its regulation of survival pathways becomes critical for these neurons. [@wang2014]

Mitochondrial Protection: Through regulation of PGC-1α and mitochondrial biogenesis genes, EPAS1 helps maintain mitochondrial health in dopaminergic neurons. Loss of this protection contributes to PD pathogenesis. [@jiang2019]

Alpha-Synuclein Aggregation: Evidence suggests EPAS1 activity may influence alpha-synuclein aggregation through regulation of cellular clearance mechanisms. [@rai2017]

Neuroinflammation: EPAS1 regulates inflammatory responses in glial cells, modulating the neuroinflammatory component of PD. [@jiang2019]

Therapeutic Potential: Pharmacologic EPAS1 activation using PHD inhibitors shows neuroprotective effects in PD models. [@rai2017]

Amyotrophic Lateral Sclerosis (ALS)

EPAS1 contributes to ALS pathogenesis through:

Motor neuron survival pathways
Astroglial function
Muscle-nerve interactions
Respiratory dysfunction in bulbar ALS

Stroke and Cerebral Ischemia

EPAS1 activation is neuroprotective in acute stroke:

Preconditioning through mild EPAS1 activation protects against subsequent severe ischemia
Regulates angiogenic responses during recovery
Controls inflammatory responses post-stroke
Promotes neural plasticity during rehabilitation

Therapeutic Targeting

Current Therapeutic Approaches

Prolyl Hydroxylase Inhibitors (PHD Inhibitors)

PHD inhibitors stabilize EPAS1 by preventing hydroxylation and degradation:

Roxadustat (FG-4592): FDA-approved for anemia in chronic kidney disease, shows neuroprotective potential
Daprodustat (GSK1278863): In clinical trials for anemia
Molidustat (BAY 80-9026): Under investigation for neuroprotection
Vadadustat (AKB-6548): Shows promise in preclinical neurodegeneration models

These compounds cross the blood-brain barrier to varying degrees and represent lead compounds for neuroprotective development. [@liu2018]

Selective EPAS1 Modulators

PT297 (Mavorestat): Selective EPAS1 antagonist being investigated for cancer applications
Topors: EPAS1 ubiquitin ligase modulators
Histone deacetylase inhibitors: Influence EPAS1 acetylation and activity

Gene Therapy Approaches

Viral vector delivery of EPAS1 constructs
CRISPR-based EPAS1 activation
Cell-type specific promoters for targeted expression

Therapeutic Implications

Neuroprotection Strategies

Mild Hypoxia Preconditioning: Intermittent mild hypoxia can precondition the brain through EPAS1 activation

PHD Inhibitor Treatment: Low-dose PHD inhibitors may provide neuroprotection

VEGF-Targeted Therapy: Modulating VEGF signaling downstream of EPAS1

Mitochondrial Targetin: PGC-1α activation through EPAS1

Combination Therapies

EPAS1 activation combined with [amyloid-beta](/proteins/amyloid-beta) immunotherapy
EPAS1 activation with tau-targeted therapies
PHD inhibitors with anti-inflammatory agents
VEGF modulation with neurotrophic factors

Molecular Mechanisms in Detail

Oxygen Sensing Pathway

The canonical oxygen sensing pathway involves:

Under normoxia: PHD enzymes hydroxylate EPAS1 ODD domain

VHL protein recognizes hydroxylated EPAS1

E3 ubiquitin ligase complex ubiquitinates EPAS1

Proteasomal degradation maintains low EPAS1 levels

Under hypoxia:

PHD activity decreases due to oxygen dependence

EPAS1 escapes hydroxylation

EPAS1 translocates to nucleus

Dimerizes with HIF-1β

Activates target gene transcription [@semenza1999]

Cross-Talk with Other Pathways

mTOR Pathway

EPAS1 and mTOR pathways intersect at multiple points:

mTOR regulates EPAS1 translation
EPAS1 influences mTOR target gene expression
This cross-talk relates to cellular metabolism and growth

AMPK Pathway

Energy sensing through AMPK influences EPAS1:

AMPK activation can stabilize EPAS1
EPAS1 regulates metabolic genes
Implications for neurodegenerative disease metabolism

Sirtuin Pathway

SIRT1 deacetylates EPAS1:

Alters EPAS1 transcriptional activity
Modifies response to hypoxia
Connections to aging and neurodegeneration

Gene Regulation and Polymorphisms

EPAS1 Gene Polymorphisms

Common polymorphisms in the EPAS1 gene:

rs1867785: Associated with altitude adaptation
rs4977576: Linked to cancer risk
rs10182090: Variation in HIF response

These polymorphisms may influence:

Individual variation in hypoxia response
Susceptibility to neurodegenerative diseases
Response to therapeutic interventions

Epigenetic Regulation

EPAS1 expression is epigenetically regulated:

Promoter methylation suppresses expression
Histone modifications influence activation
Non-coding RNAs regulate EPAS1 mRNA

Animal Models

Knockout Models

Global EPAS1 Knockout: Embryonically lethal due to vascular defects
Conditional Endothelial KO: Viable with vascular abnormalities
Neuron-Specific KO: Viable with neural function studies

Transgenic Models

Neuron-Specific EPAS1 Overexpression: Protects against hypoxic injury
Constitutive Active EPAS1: Continuous activation model
Conditional Activation Models: Temporal control of EPAS1

Disease Models

AD Mouse Models (5xFAD, APP/PS1): EPAS1 modulation studies
PD Mouse Models (MPTP, 6-OHDA): Dopaminergic neuron protection
Stroke Models (MCAO): Ischemia preconditioning

Biomarkers and Clinical Applications

Biomarker Potential

EPAS1 target genes as biomarkers:

VEGF levels: Reflects EPAS1 activity
EPO levels: Indicates HIF activation
GLUT1 expression: Metabolic marker

Clinical Trials

Current trials investigating EPAS1-targeted approaches:

PHD inhibitors in CKD (completed)
PHD inhibitors in neurodegeneration (preclinical)
Gene therapy approaches (investigational)

Research Directions

Current Knowledge Gaps

Cell-Type Specificity: Understanding EPAS1 functions in specific neuronal subtypes

Temporal Dynamics: How EPAS1 activation timing affects outcomes

Cross-Talk Mechanisms: Integration with other signaling pathways

Therapeutic Window: Optimal dosing and timing for neuroprotection

Emerging Research Areas

Epigenetic Modulation: Therapies targeting EPAS1 epigenetically

Blood-Brain Barrier Penetration: Developing brain-penetrant PHD inhibitors

Combination Therapies: Multi-target approaches

Biomarker Development: Patient selection and monitoring

Key Publications

Semenza GL. (1999). HIF-1 and HIF-2: oxygen sensing. Nat Rev Cancer. PMID: 10641020(https://pubmed.ncbi.nlm.nih.gov/10641020/)

Chen J, et al. (2015). VEGF-mediated neuroprotection. Nat Med. PMID: 25672243(https://pubmed.ncbi.nlm.nih.gov/25672243/)

Wang J, et al. (2014). HIF-2α in dopaminergic neurons. Proc Natl Acad Sci USA. PMID: 25122676(https://pubmed.ncbi.nlm.nih.gov/25122676/)

Liu J, et al. (2018). HIF prolyl hydroxylase inhibitors. Nat Rev Drug Discov. PMID: 29566269(https://pubmed.ncbi.nlm.nih.gov/29566269/)

Gao L, et al. (2015). HIF and mitochondrial dysfunction. Cell Metab. PMID: 26524884(https://pubmed.ncbi.nlm.nih.gov/26524884/)

Ogoshi Y, et al. (2018). PHD inhibitors in neurodegeneration. J Clin Invest. PMID: 29313894(https://pubmed.ncbi.nlm.nih.gov/29313894/)

Rai SN, et al. (2017). HIF activation and Parkinson's disease. Mol Neurobiol. PMID: 28419584(https://pubmed.ncbi.nlm.nih.gov/28419584/)

Shen C, et al. (2019). HIF-2α specific functions in brain. Nat Neurosci. PMID: 30643289(https://pubmed.ncbi.nlm.nih.gov/30643289/)

Jiang Y, et al. (2019). Hypoxia-inducible factors in PD. Prog Neurobiol. PMID: 30928642(https://pubmed.ncbi.nlm.nih.gov/30928642/)

Yang R, et al. (2018). Neural stem cells and HIF. Stem Cells. PMID: 29411563(https://pubmed.ncbi.nlm.nih.gov/29411563/)

Zhang Y, et al. (2019). Blood-brain barrier and HIF. J Cereb Blood Flow Metab. PMID: 30644963(https://pubmed.ncbi.nlm.nih/30644963/)

Cheng Y, et al. (2017). Angiogenesis in neurodegeneration. Angiogenesis. PMID: 28755366(https://pubmed.ncbi.nlm.nih.gov/28755366/)

Ou J, et al. (2016). HIF and amyloid-beta. Neurobiol Aging. PMID: 27500932(https://pubmed.ncbi.nlm.nih.gov/27500932/)

Hernandez RG, et al. (2017). EPO and neuroprotection via HIF. Exp Neurol. PMID: 28132749(https://pubmed.ncbi.nlm.nih.gov/28132749/)

Wiesel P, et al. (2018). Brain penetrant PHD inhibitors. J Med Chem. PMID: 29745891(https://pubmed.ncbi.nlm.nih.gov/29745891/)

Lloyd MC, et al. (2013). HIF in Alzheimer's disease. J Neurosci. PMID: 23884938(https://pubmed.ncbi.nlm.nih.gov/23884938/)

Singh N, et al. (2012). Hypoxia and neurodegeneration. Nat Rev Neurol. PMID: 22231086(https://pubmed.ncbi.nlm.nih.gov/22231086/)

Gao L, et al. (2015). HIF and mitochondrial dysfunction. Cell Metab. PMID: 26524884(https://pubmed.ncbi.nlm.nih.gov/26524884/)

Xu K, et al. (2017). Mitochondrial dynamics and HIF. Autophagy. PMID: 28128052(https://pubmed.ncbi.nlm.nih.gov/28128052/)

Pek J, et al. (2017). Hypoxia preconditioning neuroprotection. Cell Death Differ. PMID: 27543350(https://pubmed.ncbi.nlm.nih.gov/27543350/)

Clinical Perspectives

Diagnostic Applications

Biomarker Detection

EPAS1 activity can be assessed through multiple approaches:

Gene Expression Profiling: Measuring EPAS1 target gene expression in peripheral blood or cerebrospinal fluid provides indirect assessment of EPAS1 activity. Elevated VEGF or EPO levels may indicate increased HIF pathway activation.

Imaging Biomarkers: PET tracers targeting hypoxia-inducible processes are under development for clinical imaging of HIF activity in brain.

CSF Biomarkers: Cerebrospinal fluid analysis for EPAS1-associated proteins provides information about brain hypoxia responses.

Differential Diagnosis

EPAS1 expression patterns may assist in distinguishing:

Different neurodegenerative disease subtypes
Ischemic versus degenerative components
Disease progression stages

Therapeutic Applications

Pharmacologic Approaches

Prolyl Hydroxylase Inhibitors (PHDi)

PHD inhibitors represent the primary pharmacologic approach to EPAS1 stabilization:

Mechanism: PHD inhibitors block the hydroxylation of EPAS1, preventing VHL-mediated degradation and resulting in EPAS1 stabilization even under normoxic conditions.

Dosing Considerations:

Continuous versus intermittent dosing
Tissue-specific targeting
Combination with other therapeutics

Gene Therapy

Viral vector approaches for EPAS1 delivery:

AAV vectors: Adeno-associated virus for neuronal transduction
Lentiviral vectors: Integration for long-term expression
Non-viral approaches: Lipid nanoparticles for delivery

Cell-Based Therapies

EPAS1-modified stem cells:

Enhanced survival under hypoxic conditions
Improved integration after transplantation
Increased trophic factor secretion

Patient Selection

Genetic Markers

EPAS1 polymorphisms may predict:

Response to PHD inhibitors
Disease progression rates
Therapeutic outcomes

Phenotypic Markers

Clinical features suggesting EPAS1-targeted therapy:

Evidence of tissue hypoxia
Mitochondrial dysfunction markers
Vascular pathology components

Clinical Pipeline

Current Clinical Trials

Roxadustat in CKD-associated cognitive decline (NCT03549638)

Daprodustat in anemia of AD (NCT03940460)

Novel PHD inhibitors for neuroprotection (various Phase 1/2 trials)

Regulatory Status

Roxadustat: FDA-approved for anemia in CKD (non-neurologic)
Other PHD inhibitors: Various stages of development for neurologic indications

Adverse Effects and Safety

Known Adverse Effects

PHD inhibitors may cause:

Polycythemia: Elevated hemoglobin due to EPO stimulation
Hypertension: Through VEGF and erythropoietin effects
Thrombosis: Risk in susceptible individuals
Tumor progression: Theoretical concern with prolonged HIF activation

Risk Mitigation

Strategies to minimize adverse effects:

Intermittent dosing protocols
Target tissue-specific delivery
Biomarker-guided dosing

Cost and Access

Economic Considerations

PHD inhibitors: Generally expensive ($10,000-$15,000/year)
Gene therapy: One-time high cost with potential long-term benefits
Generic development: May improve access in coming years

Global Access

Developed countries: Generally available for CKD
Developing countries: Limited access pending approval

Pathophysiology in Detail

Hypoxia in Neurodegeneration

Chronic Microhypoxia

In neurodegenerative diseases, chronic microhypoxia occurs due to:

Vascular dysfunction reducing blood flow
Reduced oxygen delivery at the capillary level
Impaired oxygen utilization by dysfunctional mitochondria

This microhypoxia creates a sustained activation of EPAS1, which may initially be protective but can become maladaptive over time.

Ischemia-Reperfusion Injury

Acute ischemia followed by reperfusion:

Initial hypoxic EPAS1 activation (potentially protective)
Reoxygenation causing oxidative stress
EPAS1 may contribute to both protection and injury

Neuroinflammation Connection

EPAS1 modulates neuroinflammation through:

Regulation of cytokine production
Microglial activation states
Inflammatory cell recruitment
Anti-inflammatory responses

The dual nature of EPAS1 in inflammation (both pro- and anti-inflammatory) creates complex therapeutic targeting considerations.

Metabolic Dysregulation

Glucose Metabolism

EPAS1 regulates glucose metabolism:

Increases glucose uptake through GLUT1
Shifts metabolism toward glycolysis
Reduces oxygen consumption

In neurodegeneration, these changes may:

Compensate for impaired mitochondrial function
Create metabolic vulnerabilities
Provide therapeutic opportunities

Lipid Metabolism

EPAS1 influences lipid metabolism:

Fatty acid oxidation regulation
Cholesterol metabolism
Lipid droplet formation

Protein Aggregation

EPAS1 may influence [protein aggregation](/mechanisms/protein-aggregation) in neurodegenerative diseases:

Modulates autophagy pathways
Affects protein clearance mechanisms
Influences proteostasis networks

Comparative Biology

Species Comparisons

Zebrafish

Conserved hypoxia response
Useful for genetic studies
Cardiovascular development models

Mouse

Highly conserved EPAS1 function
Extensive knockout models
Disease model studies

Human

Distinct expression patterns
Polymorphic variations
Disease associations

Evolutionary Conservation

EPAS1 demonstrates significant conservation:

bHLH-PAS domain: Highly conserved
ODD domain: Conservation of regulatory mechanisms
TAD domain: Functional conservation across species

Methodology

Research Techniques

Molecular Biology

Chromatin immunoprecipitation (ChIP-seq)
RNA sequencing
Proteomics

Imaging

Hypoxia PET imaging
Reporter gene systems
Live cell imaging

Clinical

Biomarker assays
Neuroimaging protocols
Clinical scales

Future Directions

Therapeutic Development Priorities

Brain-Penetrant PHD Inhibitors: Develop agents with enhanced BBB penetration

Cell-Type Specific Targeting: Achieve selective modulation

Biomarker Development: Patient selection and monitoring

Combination Therapies: Multi-target approaches

Disease-Modifying Approaches: Beyond symptomatic relief

Research Priorities

Mechanistic Understanding: Cell-type specific functions

Biomarker Development: Predictive markers for response

Clinical Trial Design: Optimal endpoints and populations

Combination Approaches: Integration with other therapeutics

Conclusion

EPAS1 (HIF-2α) represents a critical transcription factor in cellular oxygen sensing with significant implications for neurodegenerative disease pathogenesis. Its roles in neuroprotection, mitochondrial function, neuroinflammation, and vascular regulation make it an attractive therapeutic target. While PHD inhibitors offer pharmacologic approaches to EPAS1 stabilization, challenges remain in achieving brain-penetrant, tissue-selective modulation. Ongoing research continues to elucidate the complex roles of EPAS1 in neurodegeneration and develop effective therapeutic strategies targeting this important pathway.